<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0005039'>Hypoxia</z:mp> and serum <z:mpath ids='MPATH_63'>depletion</z:mpath> are common features of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> that occur upon antiangiogenesis, irradiation and chemotherapy across a wide variety of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells expressing CD133, a marker for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> initiating or stem cells, are enriched and survive under <z:mp ids='MP_0005039'>hypoxia</z:mp> and serum <z:mpath ids='MPATH_63'>depletion</z:mpath> conditions, whereas CD133- cells undergo <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>CD133+ <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells increase <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cell and epithelial-mesenchymal transition properties </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, via screening a panel of tyrosine and serine/threonine kinase pathways, we identified Hsp27 is constitutively activated in CD133+ cells rather than CD133- cell under <z:mp ids='MP_0005039'>hypoxia</z:mp> and serum <z:mpath ids='MPATH_63'>depletion</z:mpath> conditions </plain></SENT>
<SENT sid="4" pm="."><plain>However, there was no difference in Hsp27 activation between CD133+ and CD133- cells under <z:mpath ids='MPATH_458'>normal</z:mpath> growth condition </plain></SENT>
<SENT sid="5" pm="."><plain>Hsp27 activation, which was mediated by the p38MAPK-MAPKAPK2-Hsp27 pathway, is required for CD133+ cells to inhibit caspase 9 and 3 cleavage </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, inhibition of Hsp27 signaling sensitizes CD133+ cells to <z:mp ids='MP_0005039'>hypoxia</z:mp> and serum <z:mpath ids='MPATH_63'>depletion</z:mpath> -induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, the antiapoptotic pathway is also activated in spheroid culture-enriched CD133+ <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells from a variety of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> cells including lung, brain and <z:e sem="disease" ids="C0153381" disease_type="Neoplastic Process" abbrv="">oral cancer</z:e>, suggesting it is a common pathway activated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells from multiple <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, activation of PP2A or inactivation of the p38MAPK-MAPKAPK2-Hsp27 pathway may develop new strategies for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy by suppression of their TIC population </plain></SENT>
</text></document>